Multiple gene and pathway-level targets

The term Multiple gene and pathway-level targets refers to a therapeutic strategy in polypharmacology where a single drug or a combination of agents is used to modulate several distinct molecular entities or biological pathways simultaneously (Source: PubMed, PMID: 22532025). This approach is essential for treating complex, multifactorial diseases like cancer, where redundant signaling networks often allow cells to bypass the inhibition of a single target (Source: NIH, National Cancer Institute). By hitting multiple nodes within a network, these therapies aim to enhance efficacy and prevent the development of drug resistance (Source: Nature Reviews Drug Discovery). Common examples include multi-kinase inhibitors like sorafenib, which targets various receptors including VEGFR and PDGFR, as well as the Raf signaling pathway (Source: PubChem). While this strategy can be more effective than single-target therapy, it also carries a higher risk of off-target effects and cumulative toxicity due to the broad modulation of biological processes (Source: StatPearls). Consequently, identifying specific biomarkers for patient selection remains a significant challenge in the development of multi-target therapies.

Other names

Polypharmacology targetsMulti-target therapyNetwork-based targetsSystems pharmacology targetsPromiscuous drug targets

Simultaneous modulation of multiple molecular targets or signaling pathways to achieve synergistic therapeutic effects and overcome biological redundancy.